Allergan (NYSE:AGN) said today that it closed its $2.48 billion acquisition of Zeltiq Aesthetics Inc. (NSDQ:ZLTQ) and its portfolio of body-contouring products.
Zeltiq’s FDA-approved CoolSculpting system uses a cooling mechanism to reduce the appearance of fat which has not responded to diet or exercise, without disturbing surrounding tissue.
Get the full story at our sister site, Drug Delivery Business News.
The post Allergan closes $2.4B Zeltiq acquisition appeared first on MassDevice.